Perspective Therapeutics Inc. (CATX) - Net Assets
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) has net assets worth $347.44 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($410.77 Million) and total liabilities ($63.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Perspective Therapeutics Inc. to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $347.44 Million |
| % of Total Assets | 84.58% |
| Annual Growth Rate | 23.11% |
| 5-Year Change | 278.89% |
| 10-Year Change | 3517.53% |
| Growth Volatility | 191.47 |
Perspective Therapeutics Inc. - Net Assets Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Perspective Therapeutics Inc. total assets for the complete picture of this company's asset base.
Annual Net Assets for Perspective Therapeutics Inc. (1994–2025)
The table below shows the annual net assets of Perspective Therapeutics Inc. from 1994 to 2025. For live valuation and market cap data, see Perspective Therapeutics Inc. (CATX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $207.03 Million | -28.77% |
| 2024-12-31 | $290.67 Million | +286.63% |
| 2023-12-31 | $75.18 Million | +37.58% |
| 2023-06-30 | $54.64 Million | 0.00% |
| 2022-12-31 | $54.64 Million | -10.83% |
| 2022-06-30 | $61.28 Million | 0.00% |
| 2021-12-31 | $61.28 Million | -9.09% |
| 2021-06-30 | $67.41 Million | +427.72% |
| 2020-12-31 | $12.77 Million | +123.19% |
| 2020-06-30 | $5.72 Million | 0.00% |
| 2019-12-31 | $5.72 Million | -25.48% |
| 2019-06-30 | $7.68 Million | 0.00% |
| 2018-12-31 | $7.68 Million | +52.68% |
| 2018-06-30 | $5.03 Million | -52.56% |
| 2017-12-31 | $10.60 Million | 0.00% |
| 2017-06-30 | $10.60 Million | -35.36% |
| 2016-12-31 | $16.40 Million | 0.00% |
| 2016-06-30 | $16.40 Million | -21.08% |
| 2015-12-31 | $20.78 Million | 0.00% |
| 2015-06-30 | $20.78 Million | -13.25% |
| 2014-12-31 | $23.96 Million | 0.00% |
| 2014-06-30 | $23.96 Million | +346.42% |
| 2013-12-31 | $5.37 Million | 0.00% |
| 2013-06-30 | $5.37 Million | -7.77% |
| 2012-12-31 | $5.82 Million | 0.00% |
| 2012-06-30 | $5.82 Million | -9.83% |
| 2011-12-31 | $6.45 Million | 0.00% |
| 2011-06-30 | $6.45 Million | +4.14% |
| 2010-12-31 | $6.20 Million | 0.00% |
| 2010-06-30 | $6.20 Million | -37.81% |
| 2009-12-31 | $9.96 Million | 0.00% |
| 2009-06-30 | $9.96 Million | -36.84% |
| 2008-12-31 | $15.77 Million | 0.00% |
| 2008-06-30 | $15.77 Million | -30.56% |
| 2007-12-31 | $22.72 Million | 0.00% |
| 2007-06-30 | $22.72 Million | +687.20% |
| 2006-12-31 | $2.89 Million | 0.00% |
| 2006-06-30 | $2.89 Million | -74.31% |
| 2005-06-30 | $11.23 Million | 0.00% |
| 2004-12-31 | $11.23 Million | +2090.78% |
| 2004-06-30 | $-564.20K | +47.90% |
| 2003-12-31 | $-1.08 Million | 0.00% |
| 2003-06-30 | $-1.08 Million | -4.89% |
| 2002-12-31 | $-1.03 Million | 0.00% |
| 2002-06-30 | $-1.03 Million | +19.48% |
| 2001-12-31 | $-1.28 Million | -4.76% |
| 2000-12-31 | $-1.22 Million | +4.54% |
| 2000-06-30 | $-1.28 Million | +39.95% |
| 1999-12-31 | $-2.14 Million | -74.46% |
| 1999-06-30 | $-1.22 Million | +40.91% |
| 1998-12-31 | $-2.07 Million | +2.99% |
| 1998-06-30 | $-2.14 Million | -12.23% |
| 1997-12-31 | $-1.90 Million | +8.15% |
| 1997-06-30 | $-2.07 Million | -221.95% |
| 1996-12-31 | $-643.46K | +66.18% |
| 1996-06-30 | $-1.90 Million | -743.43% |
| 1995-12-31 | $295.71K | +145.96% |
| 1995-06-30 | $-643.46K | -317.59% |
| 1994-12-31 | $295.71K | 0.00% |
| 1994-06-30 | $295.71K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Perspective Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33144464600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $74.00K | 0.04% |
| Other Comprehensive Income | $110.00K | 0.05% |
| Other Components | $541.69 Million | 261.65% |
| Total Equity | $207.03 Million | 100.00% |
Perspective Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Perspective Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Ruihe Construction Decoration Co Ltd
SHE:002620
|
$442.47 Million |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
$442.48 Million |
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NYSE:HQ
|
$442.49 Million |
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
$442.50 Million |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
$442.10 Million |
|
Qingdao Daneng Environmental Protection Equipment Co Ltd
SHG:688501
|
$442.09 Million |
|
Cloudberry Clean Energy As
OL:CLOUD
|
$442.07 Million |
|
Huang Hsiang Construction Corp
TW:2545
|
$442.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Perspective Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 290,668,000 to 207,031,000, a change of -83,637,000 (-28.8%).
- Net loss of 103,121,000 reduced equity.
- New share issuances of 9,986,000 increased equity.
- Other comprehensive income increased equity by 161,000.
- Other factors increased equity by 9,337,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-103.12 Million | -49.81% |
| Share Issuances | $9.99 Million | +4.82% |
| Other Comprehensive Income | $161.00K | +0.08% |
| Other Changes | $9.34 Million | +4.51% |
| Total Change | $- | -28.77% |
Book Value vs Market Value Analysis
This analysis compares Perspective Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.87x to 1.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-06-30 | $1.03 | $3.98 | x |
| 1995-06-30 | $-2.24 | $3.98 | x |
| 1995-12-31 | $1.03 | $3.98 | x |
| 1996-06-30 | $-6.62 | $3.98 | x |
| 1996-12-31 | $-2.24 | $3.98 | x |
| 1997-06-30 | $-6.38 | $3.98 | x |
| 1997-12-31 | $-5.86 | $3.98 | x |
| 1998-06-30 | $-6.49 | $3.98 | x |
| 1998-12-31 | $-6.29 | $3.98 | x |
| 1999-06-30 | $-3.72 | $3.98 | x |
| 1999-12-31 | $-6.49 | $3.98 | x |
| 2000-12-31 | $-3.72 | $3.98 | x |
| 2001-12-31 | $-3.89 | $3.98 | x |
| 2002-06-30 | $-3.14 | $3.98 | x |
| 2002-12-31 | $-3.14 | $3.98 | x |
| 2003-06-30 | $-3.29 | $3.98 | x |
| 2003-12-31 | $-3.29 | $3.98 | x |
| 2004-06-30 | $-0.70 | $3.98 | x |
| 2004-12-31 | $2.00 | $3.98 | x |
| 2005-06-30 | $4.76 | $3.98 | x |
| 2006-06-30 | $0.24 | $3.98 | x |
| 2006-12-31 | $0.24 | $3.98 | x |
| 2007-06-30 | $1.27 | $3.98 | x |
| 2007-12-31 | $1.27 | $3.98 | x |
| 2008-06-30 | $0.69 | $3.98 | x |
| 2008-12-31 | $0.69 | $3.98 | x |
| 2009-06-30 | $0.43 | $3.98 | x |
| 2009-12-31 | $0.43 | $3.98 | x |
| 2010-06-30 | $0.27 | $3.98 | x |
| 2010-12-31 | $0.27 | $3.98 | x |
| 2011-06-30 | $0.26 | $3.98 | x |
| 2011-12-31 | $0.26 | $3.98 | x |
| 2012-06-30 | $0.20 | $3.98 | x |
| 2012-12-31 | $0.20 | $3.98 | x |
| 2013-06-30 | $0.16 | $3.98 | x |
| 2013-12-31 | $0.16 | $3.98 | x |
| 2014-06-30 | $0.56 | $3.98 | x |
| 2014-12-31 | $0.56 | $3.98 | x |
| 2015-06-30 | $0.38 | $3.98 | x |
| 2015-12-31 | $0.38 | $3.98 | x |
| 2016-06-30 | $0.30 | $3.98 | x |
| 2016-12-31 | $0.30 | $3.98 | x |
| 2017-06-30 | $0.19 | $3.98 | x |
| 2017-12-31 | $0.19 | $3.98 | x |
| 2018-06-30 | $0.09 | $3.98 | x |
| 2018-12-31 | $0.11 | $3.98 | x |
| 2019-06-30 | $0.11 | $3.98 | x |
| 2019-12-31 | $0.08 | $3.98 | x |
| 2020-06-30 | $0.08 | $3.98 | x |
| 2020-12-31 | $0.23 | $3.98 | x |
| 2021-06-30 | $0.65 | $3.98 | x |
| 2021-12-31 | $4.31 | $3.98 | x |
| 2022-06-30 | $0.43 | $3.98 | x |
| 2022-12-31 | $1.00 | $3.98 | x |
| 2023-06-30 | $0.38 | $3.98 | x |
| 2023-12-31 | $1.37 | $3.98 | x |
| 2024-12-31 | $4.51 | $3.98 | x |
| 2025-12-31 | $2.80 | $3.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Perspective Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11665.27%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-49.81%) is below the historical average (-44.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -147.98% | -6.45% | 2.36x | 9.73x | $-467.17K |
| 1995 | 0.00% | -6.45% | 3.46x | 0.00x | $-373.25K |
| 1995 | -147.98% | -6.45% | 2.36x | 9.73x | $-467.17K |
| 1996 | 0.00% | -12.01% | 4.49x | 0.00x | $-748.90K |
| 1996 | 0.00% | -12.01% | 3.98x | 0.00x | $-874.82K |
| 1997 | 0.00% | -26.06% | 6.29x | 0.00x | $-1.94 Million |
| 1997 | 0.00% | -26.06% | 4.74x | 0.00x | $-1.96 Million |
| 1998 | 0.00% | -5.43% | 6.68x | 0.00x | $-212.53K |
| 1998 | 0.00% | -5.43% | 5.98x | 0.00x | $-218.92K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.14K |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $74.00K |
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $1.95 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $62.58K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $37.60K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $338.36K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $49.22K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $49.22K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.61K |
| 2004 | -38.01% | -2116.28% | 0.01x | 2.90x | $-5.39 Million |
| 2005 | 0.67% | 0.00% | 0.00x | 2.90x | $-1.05 Million |
| 2006 | -284.79% | -412.08% | 0.35x | 1.96x | $-8.51 Million |
| 2006 | -284.79% | -412.08% | 0.35x | 1.96x | $-8.51 Million |
| 2007 | -42.28% | -167.39% | 0.22x | 1.15x | $-11.88 Million |
| 2007 | -42.28% | -167.39% | 0.22x | 1.15x | $-11.88 Million |
| 2008 | -54.25% | -119.54% | 0.40x | 1.13x | $-10.13 Million |
| 2008 | -54.25% | -119.54% | 0.40x | 1.13x | $-10.13 Million |
| 2009 | -61.84% | -113.71% | 0.46x | 1.18x | $-7.16 Million |
| 2009 | -61.84% | -113.71% | 0.46x | 1.18x | $-7.16 Million |
| 2010 | -65.11% | -76.31% | 0.67x | 1.28x | $-4.65 Million |
| 2010 | -65.11% | -76.31% | 0.67x | 1.28x | $-4.65 Million |
| 2011 | -44.05% | -54.25% | 0.66x | 1.22x | $-3.49 Million |
| 2011 | -44.05% | -54.25% | 0.66x | 1.22x | $-3.49 Million |
| 2012 | -59.97% | -68.80% | 0.68x | 1.29x | $-4.07 Million |
| 2012 | -59.97% | -68.80% | 0.68x | 1.29x | $-4.07 Million |
| 2013 | -71.87% | -85.22% | 0.64x | 1.31x | $-4.39 Million |
| 2013 | -71.87% | -85.22% | 0.64x | 1.31x | $-4.39 Million |
| 2014 | -24.88% | -141.24% | 0.16x | 1.11x | $-8.35 Million |
| 2014 | -24.88% | -141.24% | 0.16x | 1.11x | $-8.35 Million |
| 2015 | -17.71% | -79.91% | 0.20x | 1.11x | $-5.76 Million |
| 2015 | -17.71% | -79.91% | 0.20x | 1.11x | $-5.76 Million |
| 2016 | -28.72% | -98.77% | 0.26x | 1.10x | $-6.35 Million |
| 2016 | -28.72% | -98.77% | 0.26x | 1.10x | $-6.35 Million |
| 2017 | -58.12% | -129.43% | 0.39x | 1.16x | $-7.22 Million |
| 2017 | -58.12% | -129.43% | 0.39x | 1.16x | $-7.22 Million |
| 2018 | -133.20% | -113.12% | 0.79x | 1.48x | $-7.20 Million |
| 2018 | -63.15% | -66.31% | 0.78x | 1.23x | $-5.62 Million |
| 2019 | -63.15% | -66.31% | 0.78x | 1.23x | $-5.62 Million |
| 2019 | -57.12% | -33.77% | 1.11x | 1.52x | $-3.84 Million |
| 2020 | -57.12% | -33.77% | 1.11x | 1.52x | $-3.84 Million |
| 2020 | -24.96% | -31.71% | 0.65x | 1.21x | $-4.47 Million |
| 2021 | -4.73% | -31.71% | 0.14x | 1.04x | $-9.93 Million |
| 2021 | -11.87% | -67.36% | 0.17x | 1.05x | $-13.40 Million |
| 2022 | -11.67% | -66.26% | 0.17x | 1.05x | $-13.28 Million |
| 2022 | -26.85% | -206.50% | 0.12x | 1.06x | $-20.13 Million |
| 2023 | -26.85% | -206.50% | 0.12x | 1.06x | $-20.13 Million |
| 2023 | -61.86% | -3243.24% | 0.01x | 1.30x | $-54.03 Million |
| 2024 | -27.27% | 0.00% | 0.00x | 1.17x | $-108.35 Million |
| 2025 | -49.81% | -11665.27% | 0.00x | 1.29x | $-123.82 Million |
Industry Comparison
This section compares Perspective Therapeutics Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,069,116,792
- Average return on equity (ROE) among peers: -106.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Perspective Therapeutics Inc. (CATX) | $347.44 Million | -147.98% | 0.18x | $442.39 Million |
| Abbott Laboratories (ABT) | $30.72 Billion | 7.71% | 1.19x | $151.99 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $18.68 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $-131.82 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $4.29 Million | -149.07% | 0.49x | $10.14 Million |
| Allurion Technologies, Inc. (ALUR) | $19.83K | -26.07% | 15.64x | $10.56 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $1.96 Million | -680.21% | 0.05x | $3.99 Million |
| Artivion Inc (AORT) | $155.25 Million | 2.58% | 0.17x | $1.09 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $153.68 Million |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more